Reviews Butrans


No reviews yet.

Butrans Drug Description
Butrans
(buprenorphine) Transdermal System for Transdermal Administration

WARNING
IMPORTANCE OF PROPER PATIENT SELECTION, POTENTIAL FOR ABUSE, AND LIMITATIONS
OF USE
Proper Patient Selection
Butrans is a transdermal formulation of buprenorphine indicated for the
management of moderate to severe chronic pain in patients requiring a continuous,
around-the-clock opioid analgesic for an extended period of time.
Potential for Abuse
Butrans contains buprenorphine which is a mu opioid partial agonist and
a Schedule III controlled substance. Butrans can be abused in a manner similar
to other opioid agonists, legal or illicit. Consider the abuse potential when
prescribing or dispensing Butrans in situations where the physician or pharmacist
is concerned about an increased risk of misuse, abuse, or diversion.
Persons at increased risk for opioid abuse include those with a personal
or family history of substance abuse (including drug or alcohol abuse or addiction)
or mental illness (e.g., major depression). Assess patients for their clinical
risks for opioid abuse or addiction prior to being prescribed opioids. Routinely
monitor all patients receiving opioids for signs of misuse, abuse and addiction.

Limitations of Use
Do not exceed a dose of one 20 mcg/hour Butrans system due to the risk of
QTc interval prolongation.
Avoid exposing the Butrans application site and surrounding area to direct
external heat sources. Temperature-dependent increases in buprenorphine release
from the system may result in overdose and death.

DRUG DESCRIPTION
Butrans is a transdermal system providing systemic delivery of buprenorphine,
a mu opioid partial agonist analgesic, continuously for 7 days. The chemical
name of buprenorphine is 6,14ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-
α-(1,1-dimethylethyl)-4, 5-epoxy-18, 19dihydro-3-hydroxy-6-methoxy-α-methyl-,
[5α, 7α, (S)]. The structural formula is:








The molecular weight of buprenorphine is 467.6; the empirical formula is C29H41NO4.
Buprenorphine occurs as a white or almost white powder and is very slightly
soluble in water, freely soluble in acetone, soluble in methanol and ether,
and slightly soluble in cyclohexane. The pKa is 8.5 and the melting point is
about 217°C.
System Components and Structure
Three different strengths of Butrans are available: 5, 10, and 20 mcg/hour
(Table 5). The active component of the system is buprenorphine. The remaining
components are pharmacologically inactive. The proportion of buprenorphine mixed
in the adhesive matrix is the same in each of the 3 strengths. The amount of
buprenorphine released from each system per hour is proportional to the active
surface area of the system. The skin is the limiting barrier to diffusion from
the system into the bloodstream.
Table 5: Butrans Product Specifications



Buprenorphine Delivery Rate (mcg/hour)
Active Surface
Area (cm²)
Total Buprenorphine
Content (mg)


Butrans 5
6.25
5


Butrans 10
12.5
10


Butrans 20
25
20



Butrans is a rectangular or square, beige-colored system consisting of a protective
liner and functional layers. Proceeding from the outer surface toward the surface
adhering to the skin, the layers are (1) a beige-colored web backing layer;
(2) an adhesive rim without buprenorphine; (3) a separating layer over the buprenorphine-containing
adhesive matrix; (4) the buprenorphine-containing adhesive matrix; and (5) a
peel-off release liner. Before use, the release liner covering the adhesive
layer is removed and discarded.
Figure 1 : Cross Section Diagram of Butrans (not to scale).








The active ingredient in Butrans is buprenorphine. The inactive ingredients
in each system are: levulinic acid, oleyl oleate, povidone, and polyacrylate
cross-linked with aluminum.
Last reviewed on RxList: 8/2/2010




Butrans Drug Description
Butrans
(buprenorphine) Transdermal System for Transdermal Administration

WARNING
IMPORTANCE OF PROPER PATIENT SELECTION, POTENTIAL FOR ABUSE, AND LIMITATIONS
OF USE
Proper Patient Selection
Butrans is a transdermal formulation of buprenorphine indicated for the
management of moderate to severe chronic pain in patients requiring a continuous,
around-the-clock opioid analgesic for an extended period of time.
Potential for Abuse
Butrans contains buprenorphine which is a mu opioid partial agonist and
a Schedule III controlled substance. Butrans can be abused in a manner similar
to other opioid agonists, legal or illicit. Consider the abuse potential when
prescribing or dispensing Butrans in situations where the physician or pharmacist
is concerned about an increased risk of misuse, abuse, or diversion.
Persons at increased risk for opioid abuse include those with a personal
or family history of substance abuse (including drug or alcohol abuse or addiction)
or mental illness (e.g., major depression). Assess patients for their clinical
risks for opioid abuse or addiction prior to being prescribed opioids. Routinely
monitor all patients receiving opioids for signs of misuse, abuse and addiction.

Limitations of Use
Do not exceed a dose of one 20 mcg/hour Butrans system due to the risk of
QTc interval prolongation.
Avoid exposing the Butrans application site and surrounding area to direct
external heat sources. Temperature-dependent increases in buprenorphine release
from the system may result in overdose and death.

DRUG DESCRIPTION
Butrans is a transdermal system providing systemic delivery of buprenorphine,
a mu opioid partial agonist analgesic, continuously for 7 days. The chemical
name of buprenorphine is 6,14ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-
α-(1,1-dimethylethyl)-4, 5-epoxy-18, 19dihydro-3-hydroxy-6-methoxy-α-methyl-,
[5α, 7α, (S)]. The structural formula is:








The molecular weight of buprenorphine is 467.6; the empirical formula is C29H41NO4.
Buprenorphine occurs as a white or almost white powder and is very slightly
soluble in water, freely soluble in acetone, soluble in methanol and ether,
and slightly soluble in cyclohexane. The pKa is 8.5 and the melting point is
about 217°C.
System Components and Structure
Three different strengths of Butrans are available: 5, 10, and 20 mcg/hour
(Table 5). The active component of the system is buprenorphine. The remaining
components are pharmacologically inactive. The proportion of buprenorphine mixed
in the adhesive matrix is the same in each of the 3 strengths. The amount of
buprenorphine released from each system per hour is proportional to the active
surface area of the system. The skin is the limiting barrier to diffusion from
the system into the bloodstream.
Table 5: Butrans Product Specifications



Buprenorphine Delivery Rate (mcg/hour)
Active Surface
Area (cm²)
Total Buprenorphine
Content (mg)


Butrans 5
6.25
5


Butrans 10
12.5
10


Butrans 20
25
20



Butrans is a rectangular or square, beige-colored system consisting of a protective
liner and functional layers. Proceeding from the outer surface toward the surface
adhering to the skin, the layers are (1) a beige-colored web backing layer;
(2) an adhesive rim without buprenorphine; (3) a separating layer over the buprenorphine-containing
adhesive matrix; (4) the buprenorphine-containing adhesive matrix; and (5) a
peel-off release liner. Before use, the release liner covering the adhesive
layer is removed and discarded.
Figure 1 : Cross Section Diagram of Butrans (not to scale).








The active ingredient in Butrans is buprenorphine. The inactive ingredients
in each system are: levulinic acid, oleyl oleate, povidone, and polyacrylate
cross-linked with aluminum.
Last reviewed on RxList: 8/2/2010




Butrans Drug Description
Butrans
(buprenorphine) Transdermal System for Transdermal Administration

WARNING
IMPORTANCE OF PROPER PATIENT SELECTION, POTENTIAL FOR ABUSE, AND LIMITATIONS
OF USE
Proper Patient Selection
Butrans is a transdermal formulation of buprenorphine indicated for the
management of moderate to severe chronic pain in patients requiring a continuous,
around-the-clock opioid analgesic for an extended period of time.
Potential for Abuse
Butrans contains buprenorphine which is a mu opioid partial agonist and
a Schedule III controlled substance. Butrans can be abused in a manner similar
to other opioid agonists, legal or illicit. Consider the abuse potential when
prescribing or dispensing Butrans in situations where the physician or pharmacist
is concerned about an increased risk of misuse, abuse, or diversion.
Persons at increased risk for opioid abuse include those with a personal
or family history of substance abuse (including drug or alcohol abuse or addiction)
or mental illness (e.g., major depression). Assess patients for their clinical
risks for opioid abuse or addiction prior to being prescribed opioids. Routinely
monitor all patients receiving opioids for signs of misuse, abuse and addiction.

Limitations of Use
Do not exceed a dose of one 20 mcg/hour Butrans system due to the risk of
QTc interval prolongation.
Avoid exposing the Butrans application site and surrounding area to direct
external heat sources. Temperature-dependent increases in buprenorphine release
from the system may result in overdose and death.

DRUG DESCRIPTION
Butrans is a transdermal system providing systemic delivery of buprenorphine,
a mu opioid partial agonist analgesic, continuously for 7 days. The chemical
name of buprenorphine is 6,14ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-
α-(1,1-dimethylethyl)-4, 5-epoxy-18, 19dihydro-3-hydroxy-6-methoxy-α-methyl-,
[5α, 7α, (S)]. The structural formula is:








The molecular weight of buprenorphine is 467.6; the empirical formula is C29H41NO4.
Buprenorphine occurs as a white or almost white powder and is very slightly
soluble in water, freely soluble in acetone, soluble in methanol and ether,
and slightly soluble in cyclohexane. The pKa is 8.5 and the melting point is
about 217°C.
System Components and Structure
Three different strengths of Butrans are available: 5, 10, and 20 mcg/hour
(Table 5). The active component of the system is buprenorphine. The remaining
components are pharmacologically inactive. The proportion of buprenorphine mixed
in the adhesive matrix is the same in each of the 3 strengths. The amount of
buprenorphine released from each system per hour is proportional to the active
surface area of the system. The skin is the limiting barrier to diffusion from
the system into the bloodstream.
Table 5: Butrans Product Specifications



Buprenorphine Delivery Rate (mcg/hour)
Active Surface
Area (cm²)
Total Buprenorphine
Content (mg)


Butrans 5
6.25
5


Butrans 10
12.5
10


Butrans 20
25
20



Butrans is a rectangular or square, beige-colored system consisting of a protective
liner and functional layers. Proceeding from the outer surface toward the surface
adhering to the skin, the layers are (1) a beige-colored web backing layer;
(2) an adhesive rim without buprenorphine; (3) a separating layer over the buprenorphine-containing
adhesive matrix; (4) the buprenorphine-containing adhesive matrix; and (5) a
peel-off release liner. Before use, the release liner covering the adhesive
layer is removed and discarded.
Figure 1 : Cross Section Diagram of Butrans (not to scale).








The active ingredient in Butrans is buprenorphine. The inactive ingredients
in each system are: levulinic acid, oleyl oleate, povidone, and polyacrylate
cross-linked with aluminum.
Last reviewed on RxList: 8/2/2010




Butrans Drug Description
Butrans
(buprenorphine) Transdermal System for Transdermal Administration

WARNING
IMPORTANCE OF PROPER PATIENT SELECTION, POTENTIAL FOR ABUSE, AND LIMITATIONS
OF USE
Proper Patient Selection
Butrans is a transdermal formulation of buprenorphine indicated for the
management of moderate to severe chronic pain in patients requiring a continuous,
around-the-clock opioid analgesic for an extended period of time.
Potential for Abuse
Butrans contains buprenorphine which is a mu opioid partial agonist and
a Schedule III controlled substance. Butrans can be abused in a manner similar
to other opioid agonists, legal or illicit. Consider the abuse potential when
prescribing or dispensing Butrans in situations where the physician or pharmacist
is concerned about an increased risk of misuse, abuse, or diversion.
Persons at increased risk for opioid abuse include those with a personal
or family history of substance abuse (including drug or alcohol abuse or addiction)
or mental illness (e.g., major depression). Assess patients for their clinical
risks for opioid abuse or addiction prior to being prescribed opioids. Routinely
monitor all patients receiving opioids for signs of misuse, abuse and addiction.

Limitations of Use
Do not exceed a dose of one 20 mcg/hour Butrans system due to the risk of
QTc interval prolongation.
Avoid exposing the Butrans application site and surrounding area to direct
external heat sources. Temperature-dependent increases in buprenorphine release
from the system may result in overdose and death.

DRUG DESCRIPTION
Butrans is a transdermal system providing systemic delivery of buprenorphine,
a mu opioid partial agonist analgesic, continuously for 7 days. The chemical
name of buprenorphine is 6,14ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-
α-(1,1-dimethylethyl)-4, 5-epoxy-18, 19dihydro-3-hydroxy-6-methoxy-α-methyl-,
[5α, 7α, (S)]. The structural formula is:








The molecular weight of buprenorphine is 467.6; the empirical formula is C29H41NO4.
Buprenorphine occurs as a white or almost white powder and is very slightly
soluble in water, freely soluble in acetone, soluble in methanol and ether,
and slightly soluble in cyclohexane. The pKa is 8.5 and the melting point is
about 217°C.
System Components and Structure
Three different strengths of Butrans are available: 5, 10, and 20 mcg/hour
(Table 5). The active component of the system is buprenorphine. The remaining
components are pharmacologically inactive. The proportion of buprenorphine mixed
in the adhesive matrix is the same in each of the 3 strengths. The amount of
buprenorphine released from each system per hour is proportional to the active
surface area of the system. The skin is the limiting barrier to diffusion from
the system into the bloodstream.
Table 5: Butrans Product Specifications



Buprenorphine Delivery Rate (mcg/hour)
Active Surface
Area (cm²)
Total Buprenorphine
Content (mg)


Butrans 5
6.25
5


Butrans 10
12.5
10


Butrans 20
25
20



Butrans is a rectangular or square, beige-colored system consisting of a protective
liner and functional layers. Proceeding from the outer surface toward the surface
adhering to the skin, the layers are (1) a beige-colored web backing layer;
(2) an adhesive rim without buprenorphine; (3) a separating layer over the buprenorphine-containing
adhesive matrix; (4) the buprenorphine-containing adhesive matrix; and (5) a
peel-off release liner. Before use, the release liner covering the adhesive
layer is removed and discarded.
Figure 1 : Cross Section Diagram of Butrans (not to scale).








The active ingredient in Butrans is buprenorphine. The inactive ingredients
in each system are: levulinic acid, oleyl oleate, povidone, and polyacrylate
cross-linked with aluminum.
Last reviewed on RxList: 8/2/2010




Butrans Drug Description
Butrans
(buprenorphine) Transdermal System for Transdermal Administration

WARNING
IMPORTANCE OF PROPER PATIENT SELECTION, POTENTIAL FOR ABUSE, AND LIMITATIONS
OF USE
Proper Patient Selection
Butrans is a transdermal formulation of buprenorphine indicated for the
management of moderate to severe chronic pain in patients requiring a continuous,
around-the-clock opioid analgesic for an extended period of time.
Potential for Abuse
Butrans contains buprenorphine which is a mu opioid partial agonist and
a Schedule III controlled substance. Butrans can be abused in a manner similar
to other opioid agonists, legal or illicit. Consider the abuse potential when
prescribing or dispensing Butrans in situations where the physician or pharmacist
is concerned about an increased risk of misuse, abuse, or diversion.
Persons at increased risk for opioid abuse include those with a personal
or family history of substance abuse (including drug or alcohol abuse or addiction)
or mental illness (e.g., major depression). Assess patients for their clinical
risks for opioid abuse or addiction prior to being prescribed opioids. Routinely
monitor all patients receiving opioids for signs of misuse, abuse and addiction.

Limitations of Use
Do not exceed a dose of one 20 mcg/hour Butrans system due to the risk of
QTc interval prolongation.
Avoid exposing the Butrans application site and surrounding area to direct
external heat sources. Temperature-dependent increases in buprenorphine release
from the system may result in overdose and death.

DRUG DESCRIPTION
Butrans is a transdermal system providing systemic delivery of buprenorphine,
a mu opioid partial agonist analgesic, continuously for 7 days. The chemical
name of buprenorphine is 6,14ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-
α-(1,1-dimethylethyl)-4, 5-epoxy-18, 19dihydro-3-hydroxy-6-methoxy-α-methyl-,
[5α, 7α, (S)]. The structural formula is:








The molecular weight of buprenorphine is 467.6; the empirical formula is C29H41NO4.
Buprenorphine occurs as a white or almost white powder and is very slightly
soluble in water, freely soluble in acetone, soluble in methanol and ether,
and slightly soluble in cyclohexane. The pKa is 8.5 and the melting point is
about 217°C.
System Components and Structure
Three different strengths of Butrans are available: 5, 10, and 20 mcg/hour
(Table 5). The active component of the system is buprenorphine. The remaining
components are pharmacologically inactive. The proportion of buprenorphine mixed
in the adhesive matrix is the same in each of the 3 strengths. The amount of
buprenorphine released from each system per hour is proportional to the active
surface area of the system. The skin is the limiting barrier to diffusion from
the system into the bloodstream.
Table 5: Butrans Product Specifications



Buprenorphine Delivery Rate (mcg/hour)
Active Surface
Area (cm²)
Total Buprenorphine
Content (mg)


Butrans 5
6.25
5


Butrans 10
12.5
10


Butrans 20
25
20



Butrans is a rectangular or square, beige-colored system consisting of a protective
liner and functional layers. Proceeding from the outer surface toward the surface
adhering to the skin, the layers are (1) a beige-colored web backing layer;
(2) an adhesive rim without buprenorphine; (3) a separating layer over the buprenorphine-containing
adhesive matrix; (4) the buprenorphine-containing adhesive matrix; and (5) a
peel-off release liner. Before use, the release liner covering the adhesive
layer is removed and discarded.
Figure 1 : Cross Section Diagram of Butrans (not to scale).








The active ingredient in Butrans is buprenorphine. The inactive ingredients
in each system are: levulinic acid, oleyl oleate, povidone, and polyacrylate
cross-linked with aluminum.
Last reviewed on RxList: 8/2/2010





Other reviews about Butrans on wordpress

Medication I Am On
  by Julie
[caption id="attachment_72" align="aligncenter" width="300" caption="Cymbalta (Duloxetine)"][/caption] Cymbalta offers relief from symptoms of depression, generalized anxiety disorder (GAD), diabetic nerve pain (DNP), and fibromyalgia. Cymbalta is not a […]


List of strongest generic tramadol
  by tura18
She haired not bloodlust thyself to outbreak. Excellence or clearchoice she interposed her eyes to feet the aardvark tones arose haze she fanbelt upon her embrace, but the […]


Sample of discussions that take place all the time re meds & supplements...
  by K H
I am asking this question for a friend... Have you tried Lyrica? Please share your opinions and experiences. Have a beautiful day. Love and hugs. ♥ -JHS Yep Didn't […]


Opium Heroine Morphine Methadone & Buprenorphine
  by ZoSoTRUTHTALK
Opium For other meanings of opium, see Opium (disambiguation). For opium-derived and opium-like substances, see Opiates and Opioids. Opium […]


tatoo script flash body coloured hyundai hand p …
  by bokaoffice
tatoo script flash body coloured hyundai hand painted carved tables mysapce bold codes wordpress baby theme sbc email accounts setup chinese symbolic statues male models ideal birth video google healing the light body send receiving hindi jokes […]


tatoo script flash body coloured hyundai hand p …
  by bokaoffice
tatoo script flash body coloured hyundai hand painted carved tables mysapce bold codes wordpress baby theme sbc email accounts setup chinese symbolic statues male models ideal birth video google healing the light body send receiving hindi jokes […]


tatoo script flash body coloured hyundai hand p …
  by zejaagni
tatoo script flash body coloured hyundai hand painted carved tables mysapce bold codes wordpress baby theme sbc email accounts setup chinese symbolic statues male models ideal birth video google healing the light body send receiving hindi jokes […]


tatoo script flash body coloured hyundai hand p …
  by zejaagni
tatoo script flash body coloured hyundai hand painted carved tables mysapce bold codes wordpress baby theme sbc email accounts setup chinese symbolic statues male models ideal birth video google healing the light body send receiving hindi jokes […]


He supposed Smith could have found out
  by xdhwtngfcxr
The disquietude of his air, the somewhat apprehensive impatience of his manner, surprised me: but I proceeded. On the Monday morning Holmes had telegraphed to the London police, […]


Trial Shows Safety, Efficacy of 7-Day Buprenorphine Patch in Opioid-Naive Patients
  by exilope
September 28, 2010 (Las Vegas, Nevada) — A transdermal application system containing the partial μ-opioid receptor agonist buprenorphine showed analgesic efficacy in the treatment of low […]



Other reviews about Butrans on web:

BuTrans patches contain the active ingredient buprenorphine, which is a type of medicine called an opioid analgesic (painkiller). It is a strong painkiller related to morphine. BuTrans


Welcome to the BuTrans.co.uk website. This site is intended as an information resource for Healthcare Professionals, Patients and Carers with an interest in pain, pain management ... Welcome to BuTrans.co.uk | BuTrans.co.uk


Are you a United States (USA) health care professional? Please click on YES or NO to confirm whether you are a health care professional in the USA. Butrans


Butrans (buprenorphine) Transdermal System is used to treat chronic pain. Includes Butrans side effects, interactions and indications. Butrans Information from Drugs.com


Moreover, a new 5, 10 and 20 mcg per hour patch is marketed as Butrans or Norspan, a once-weekly patch for moderate chronic pain not responding to non-opioids, marketed by Napp ... Buprenorphine - Wikipedia, the free encyclopedia


Learn about the prescription medication Butrans (Buprenorphine Transdermal System), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Butrans (Buprenorphine Transdermal System) Drug Information: Uses ...


BuTrans 5, 10 and 20ug/h Transdermal Patch - Summary of Product Characteristics (SPC) by Napp Pharmaceuticals Limited BuTrans 5, 10 and 20ug/h Transdermal Patch - Summary of Product ...


Butrans (buprenorphine) Transdermal System is used to treat chronic pain. Includes Butrans side effects, interactions and indications. Purdue Pharma L.P. Receives FDA Approval for Butrans ...


Welcome to the healthcare professional section of the BuTrans.co.uk website where you can find useful information about BuTrans patches, current pain management guidelines and ... UK Healthcare Professional Section | BuTrans.co.uk


Article on Guidelines for the use of Buprenorphine (BuTrans) Transdermal patch London Pain Consultants: Guidelines for the use of Buprenorphine ...





Featured Reviews

Reviews Cosmegen

Cosmegen Drug Description COSMEGEN® FOR INJECTION (dactinomycin) for Injection (Actinomycin D) WARNING COSMEGEN® (Dactinomycin for Injection) should be administered only under the supervision of a physician who is experienced...
Read More  |  Review This
Reviews Targretin

Targretin Drug Description Targretin® (bexarotene) Capsules, 75 mg Targretin® capsules are a member of the retinoid class of drugs that is associated with birth defects in humans. Targretin® capsules also caused birth...
Read More  |  Review This
Reviews Leukeran

Leukeran Drug Description LEUKERAN (chlorambucil) Tablets WARNING LEUKERAN (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans....
Read More  |  Review This
Reviews Cortone

Cortone Drug Description Cortisone Acetate Tablets, USP DRUG DESCRIPTION What are the possible side effects of cortisone (Cortone Acetate)? Get emergency medical help if you have any of these signs of an allergic reaction: hives;...
Read More  |  Review This
Reviews Butalbital Compound With Codeine

Fiorinal with Codeine Drug Description Fiorinal With Codeine (butalbital, aspirin, caffeine, and codeine phosphate) Capsule DRUG DESCRIPTION What are the possible side effects of aspirin, butalbital, caffeine, and codeine (Fiorinal...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....